Faculty Profiles - TAKEMOTO Mami

Papers - TAKEMOTO Mami

Division display 81 - 100 of about 253 ／ All the affair displays >>

A case of Kii amyotrophic lateral sclerosis/parkinsonism dementia complex presenting as progressive parkinsonism with corresponding tau imaging

Yasuyuki Ohta, Hitoshi Shimada, Ken Ikegami, Keiichiro Tsunoda, Nozomi Hishikawa, Toru Yamashita, Mami Takemoto, Yoshio Omote, Kenji Tagai, Kiwamu Matsuoka, Makoto Higuchi, Koji Abe

NEUROLOGY AND CLINICAL NEUROSCIENCE 9 ( 1 ) 124 - 126 2021.1

Retinal Amyloid Imaging for Screening Alzheimer's Disease. International journal

Koh Tadokoro, Toru Yamashita, Shuhei Kimura, Emi Nomura, Yasuyuki Ohta, Yoshio Omote, Mami Takemoto, Nozomi Hishikawa, Ryuta Morihara, Yuki Morizane, Koji Abe

Journal of Alzheimer's disease : JAD 83 ( 2 ) 927 - 934 2021

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: Cost-effective and noninvasive methods for in vivo imaging of amyloid deposition are needed to screen Alzheimer's disease (AD). Although retinal amyloid is a possible diagnostic marker of AD, there are very few studies on in vivo retinal amyloid imaging. OBJECTIVE: To examine the usefulness of in vivo imaging of retinal amyloid in AD patients. METHODS: To examine amyloid deposition, 30 Japanese subjects (10 normal control (NC), 7 with mild cognitive impairment (MCI), and 13 with AD) underwent a complete ophthalmic examination, including fundus imaging by scanning laser ophthalmoscopy before and after oral curcumin intake. RESULTS: Retinal amyloid deposition was greater in AD than in NC subjects (*p < 0.05) while MCI showed a slight but insignificant increase of retinal amyloid deposition relative to NC subjects. Retinal amyloid deposition was correlated with whole gray matter atrophy (r = 0.51, *p < 0.05) but not with the cognitive score of the Mini-Mental State Examination, nor with medial temporal lobe atrophy. CONCLUSION: The present noninvasive in vivo detection of retinal amyloid deposition is useful for screening AD patients.

DOI： 10.3233/JAD-210327

PubMed

researchmap

Immediate Beneficial Effect of Makeup Therapy on Behavioral and Psychological Symptoms of Dementia and Facial Appearance Analyzed by Artificial Intelligence Software. International journal

Koh Tadokoro, Toru Yamashita, Satoko Kawano, Junko Sato, Yoshio Omote, Mami Takemoto, Ryuta Morihara, Koichiro Nishiura, Natsuki Sagawa, Tomiko Tani, Koji Abe

Journal of Alzheimer's disease : JAD 83 ( 1 ) 57 - 63 2021

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: Possible benefits of makeup therapy, in terms of immediate and late effects on cognitive and affective functions, have not been fully proved for dementia patients. OBJECTIVE: To evaluate the immediate effect of makeup therapy on dementia patients. METHODS: Female nursing home residents with dementia received either only skin care treatment (control group, n = 17) or skin care plus makeup therapy treatment (makeup therapy group, n = 19). Cognitive, affective, and activity of daily living (ADL) scores were evaluated before and just after treatments. Apparent age and emotion were also evaluated with artificial intelligence (AI) software. RESULTS: Makeup therapy significantly improved Abe's behavioral and psychological symptoms of dementia (BPSD) score (ABS, *p < 0.05). AI software judged that makeup therapy significantly made the apparent age younger (*p < 0.05). In particular, patients with moderate ADL scores had a significantly higher happiness score in makeup therapy (*p < 0.05), with a modest correlation to the Mini-Mental State Examination (MMSE, r = 0.42, *p < 0.05). The severe baseline MMSE group reported a greater feeling of satisfaction following makeup therapy (*p < 0.05). CONCLUSION: The present makeup therapy is a promising non-pharmacological approach to immediately alleviate BPSD in female dementia patients, and the present AI software quickly and quantitatively evaluated the beneficial effects of makeup therapy on facial appearance.

DOI： 10.3233/JAD-210284

PubMed

researchmap

Cerebral Microbleeds in Patients with Parkinson's Disease and Dementia with Lewy Bodies: Comparison Using Magnetic Resonance Imaging and 99 mTc-ECD SPECT Subtraction Imaging. International journal

Mami Takemoto, Toru Yamashita, Yasuyuki Ohta, Koh Tadokoro, Yoshio Omote, Ryuta Morihara, Koji Abe

Journal of Alzheimer's disease : JAD 80 ( 1 ) 331 - 335 2021

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: Cerebral microbleeds (CMBs) in patients with Parkinson's disease (PD) or dementia with Lewy bodies (DLB) have not been adequately studied. OBJECTIVE: This study aims to find a difference in the total number, prevalence, and common locations of CMBs between PD and DLB and evaluate 99 mTc-ECD SPECT subtraction images of these two diseases. METHODS: We examined 112 patients with PD (53 males and 59 females; age: 77.4±3.6 years) and 28 age-matched patients with DLB (15 males and 13 females; age: 77.1±6.7 years) using brain magnetic resonance imaging (MRI) and 99 mTc-ECD SPECT subtraction imaging. RESULTS: The total number of CMBs was higher in patients with DLB (41.2%) than in those with PD (11.5%), and the prevalence was significantly higher in the former (0.7±1.1) than the latter (0.2±0.5, p < 0.05). The odds ratio was 5.4 (95% confidence interval [CI]: 1.7-17.4). Furthermore, CMBs were commonly located in the basal ganglia of patients with PD (6 out of 87 patients) but in the occipital lobe of patients with DLB (8 out of 17 patients). 99 mTc-ECD SPECT subtraction imaging indicated lower cerebral blood flow in the posterior cingulate gyrus among the patients with CMB-positive DLB than among those with CMB-positive PD; additionally, the cerebral blood flow was lower in the bilateral basal ganglia and midbrain among patients with CMB-positive DLB compared to those with CMB-negative DLB. CONCLUSION: A reduction in occipital glucose metabolism may be related to CMBs in the occipital lobe of patients with DLB.

DOI： 10.3233/JAD-201495

PubMed

researchmap

Tocilizumab-induced Leukoencephalopathy with a Reversible Clinical Course.

Ryo Sasaki, Nozomi Hishikawa, Emi Nomura, Yoshio Omote, Mami Takemoto, Toru Yamashita, Noriko Hatanaka, Yasuto Higashi, Koji Abe

Internal medicine (Tokyo, Japan) 59 ( 22 ) 2927 - 2930 2020.11

Language：English Publishing type：Research paper (scientific journal)

Tocilizumab (TCZ; Actemra/RoActemra) is an anti-interleukin (IL)-6 receptor antibody for the treatment of rheumatoid arthritis (RA) and other autoimmune diseases and cytokine storms. The present case is a 63-year-old female well-controlled RA patient, who presented with a progressive cognitive impairment after 34 months of TCZ administration. Brain magnetic resonance imaging (MRI) showed leukencephalopathy with a lactic acid peak in magnetic resonance spectroscopy (MRS), a decreased blood flow in single photon emission computed tomography (SPECT), and a decreased accumulation in fluorodeoxyglucose positron emission tomography (FDG-PET). The discontinuation of TCZ improved her cognitive function and brain MRI findings at 3 months after drug cessation. The present case suggests that TCZ may sometimes cause leukoencephalopathy after long-term administration, and thus the early discontinuation of TCZ is recommended to achieve a good prognosis.

DOI： 10.2169/internalmedicine.5288-20

PubMed

researchmap

Repeat sizes of NOP56 gene in a Japanese Asidan (SCA36) family with clinical anticipation. International journal

Yasuyuki Ohta, Ken Ikegami, Kota Sato, Nozomi Hishikawa, Yoshio Omote, Mami Takemoto, Toru Yamashita, Koji Abe

Journal of the neurological sciences 418 117150 - 117150 2020.11

認知機能正常者ならびに軽度認知障害における認知症周辺症状の出現

角田慶一郎, 山下徹, 小坂田陽介, 佐々木諒, 田所功, 松本菜見子, 野村恵美, 森原隆太, 中野由美子, 高橋義秋, 幡中典子, 商敬偉, 佐藤恒太, 武本麻美, 菱川望, 太田康之, 阿部康二

臨床神経学 60 ( Suppl. ) S445 - S445 2020.11

ALS患者脊髄における低酸素ストレスを可視化する

山下徹, 畠山哲宗, 佐藤恒太, 福井裕介, 菱川望, 武本麻美, 太田康之, 西山佳宏, 河井信行, 田宮隆, 阿部康二

脳循環代謝 32 ( 1 ) 102 - 102 2020.11

アルツハイマー病患者の臨床的進行予測因子についての検討

菱川望, 表芳夫, 武本麻美, 太田康之, 山下徹, 阿部康二

臨床神経学 60 ( Suppl. ) S424 - S424 2020.11

PDDとDLBの認知機能と情動機能、脳血流画像の比較検討

武本麻美, 田所功, 表芳夫, 菱川望, 太田康之, 山下徹, 阿部康二

臨床神経学 60 ( Suppl. ) S408 - S408 2020.11

幹細胞移植による虚血脳のタンパク分解分子機構への影響

田所功, 福井裕介, 山下徹, 劉夏, 角田慶一郎, 商敬偉, 表芳夫, 武本麻美, 菱川望, 太田康之, 阿部康二

脳循環代謝 32 ( 1 ) 124 - 124 2020.11

同種骨髄移植が有用であった大脳型に進展した副腎白質ジストロフィーの1例

表芳夫, 佐藤恒太, 浦田知宏, 藤井伸治, 下澤伸行, 山下徹, 武本麻美, 菱川望, 太田康之, 阿部康二

臨床神経学 60 ( Suppl. ) S416 - S416 2020.11

Therapeutic benefit of Muse cells in a mouse model of amyotrophic lateral sclerosis. International journal

Toru Yamashita, Yoshihiro Kushida, Shohei Wakao, Koh Tadokoro, Emi Nomura, Yoshio Omote, Mami Takemoto, Nozomi Hishikawa, Yasuyuki Ohta, Mari Dezawa, Koji Abe

Scientific reports 10 ( 1 ) 17102 - 17102 2020.10

Language：English Publishing type：Research paper (scientific journal)

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive motor neuron loss. Muse cells are endogenous reparative pluripotent-like stem cells distributed in various tissues. They can selectively home to damaged sites after intravenous injection by sensing sphingosine-1-phosphate produced by damaged cells, then exert pleiotropic effects, including tissue protection and spontaneous differentiation into tissue-constituent cells. In G93A-transgenic ALS mice, intravenous injection of 5.0 × 104 cells revealed successful homing of human-Muse cells to the lumbar spinal cords, mainly at the pia-mater and underneath white matter, and exhibited glia-like morphology and GFAP expression. In contrast, such homing or differentiation were not recognized in human mesenchymal stem cells but were instead distributed mainly in the lung. Relative to the vehicle groups, the Muse group significantly improved scores in the rotarod, hanging-wire and muscle strength of lower limbs, recovered the number of motor neurons, and alleviated denervation and myofiber atrophy in lower limb muscles. These results suggest that Muse cells homed in a lesion site-dependent manner and protected the spinal cord against motor neuron death. Muse cells might also be a promising cell source for the treatment of ALS patients.

DOI： 10.1038/s41598-020-74216-4

PubMed

researchmap

Direct arterial damage and neurovascular unit disruption by mechanical thrombectomy in a rat stroke model

Ryo Sasaki, Toru Yamashita, Koh Tadokoro, Namiko Matsumoto, Emi Nomura, Yoshio Omote, Mami Takemoto, Nozomi Hishikawa, Yasuyuki Ohta, Koji Abe

JOURNAL OF NEUROSCIENCE RESEARCH 98 ( 10 ) 2018 - 2026 2020.10

脳梗塞後に神経細胞を新たに生み出し再生を目指す脳内グリア細胞から神経細胞を誘導する新技術の確立

山下徹, 商敬偉, 中野由美子, 森原隆太, 佐藤恒太, 武本麻美, 菱川望, 太田康之, 阿部康二

神経治療学 37 ( 6 ) S253 - S253 2020.10

幹細胞移植による虚血脳のタンパク分解分子機構への影響

田所功, 福井裕介, 山下徹, 劉夏, 角田慶一郎, 商敬偉, 表芳夫, 武本麻美, 菱川望, 太田康之, 阿部康二

神経治療学 37 ( 6 ) S253 - S253 2020.10

実は見逃されている血管性認知症の危険因子

山下徹, 野崎洋明, 涌谷陽介, 田所功, 野村恵美, 菱川望, 武本麻美, 太田康之, 小野寺理, 阿部康二

Dementia Japan 34 ( 4 ) 493 - 493 2020.10

アルツハイマー病患者の主観的・客観的睡眠障害

田所功, 太田康之, 菱川望, 野村恵美, 涌谷陽介, 高尾芳樹, 表芳夫, 武本麻美, 山下徹, 阿部康二

Dementia Japan 34 ( 4 ) 477 - 477 2020.10

Clinical anticipation of disease onset in a Japanese Asidan (SCA36) family. International journal

Yasuyuki Ohta, Ken Ikegami, Kota Sato, Nozomi Hishikawa, Yoshio Omote, Mami Takemoto, Toru Yamashita, Koji Abe

Journal of the neurological sciences 416 ( 15 ) 117043 - 117043 2020.9

A case of triple seronegative myasthenia gravis with Graves' disease ameliorated after the removal of enlarged thymus with elevated uptake in fluorine-18 fluorodeoxyglucose positron emission tomography

Namiko Matsumoto, Yoshio Omote, Yumiko Nakano, Mami Takemoto, Nozomi Hishikawa, Kota Sato, Yasuyuki Ohta, Toru Yamashita, Tomohiro Toji, Koji Abe

NEUROLOGY AND CLINICAL NEUROSCIENCE 8 ( 5 ) 313 - 316 2020.9

　 PREV - NEXT 　

< TAKEMOTO Mami >

Papers - TAKEMOTO Mami